Granted Patent
B2
US 12,534,726 · App. 19/084,507 · Granted Jan 27, 2026
Composition and method for inhibiting angiotensinogen (AGT) protein expression
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided are a composition and method for inhibiting angiotensinogen (AGT) protein expression. Specifically, provided are a composition and method capable of being used for reducing AGT gene expression and treating AGT-related diseases and disorders. Provided are an AGT dsRNA reagent capable of being used for reducing AGT expression in a cell and an object, an AGT antisense polynucleotide reagent, a composition containing the AGT dsRNA reagent, and a composition containing the AGT antisense polynucleotide reagent.
Claims (10)
1 . A double-stranded RNA (dsRNA) agent for inhibiting angiotensinogen (AGT) gene expression, wherein the dsRNA agent comprises a sense strand and an antisense strand, wherein the sense strand comprises SEQ ID NO:526 ((GLS-15)*(Invab)*caccagcuUgUuUgugaaaca*(Invab)), wherein the antisense strand comprises SEQ ID NO:527 (u*G*uuucAcaaaCaAgCugg*u*g), and wherein each nucleotide in lower case has a 2′-O-methyl (2′-OMe) modification, each nucleotide in upper case has a 2′-fluoro modification, each star (*) is a phosphorothioate linkage, each Invab is an inverted abasic residue, and GLS-15 is
2 . A composition comprising the dsRNA agent of claim 1 and a pharmaceutically acceptable carrier.
3 . The composition of claim 2 , wherein the composition is packaged in a kit, container, pack, dispenser, prefilled syringe, or vial.
4 . The composition of claim 2 , wherein the composition is formulated for subcutaneous administration.
5 . The composition of claim 2 , wherein the pharmaceutically acceptable carrier comprises a sodium salt.
6 . A double-stranded RNA (dsRNA) agent for inhibiting angiotensinogen (AGT) gene expression, wherein the dsRNA agent comprises a sense strand and an antisense strand, wherein the sense strand consists of SEQ ID NO:526 ((GLS-15)*(Invab)*caccagcuUgUuUgugaaaca*(Invab)), wherein the antisense strand consists of SEQ ID NO:527 (u*G*uuucAcaaaCaAgCugg*u*g), and wherein each nucleotide in lower case has a 2′-O-methyl (2′-OMe) modification, each nucleotide in upper case has a 2′-fluoro modification, each star (*) is a phosphorothioate linkage, each Invab is an inverted abasic residue, and GLS-15 is
7 . A composition comprising the dsRNA agent of claim 6 and a pharmaceutically acceptable carrier.
8 . The composition of claim 7 , wherein the pharmaceutically acceptable carrier comprises a sodium salt.
9 . The composition of claim 7 , wherein the composition is packaged in a kit, container, pack, dispenser, prefilled syringe, or vial.
10 . The composition of claim 7 , wherein the composition is formulated for subcutaneous administration.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 14, 2025
From: SHU, DONGXU; SHAO, PENGCHENG PATRICK
To: SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD.
Reel/Frame 073064/0820 →
Priority Claims (2)
WO PCT/CN2021/130832
· Nov 16, 2021
· international
WO PCT/CN2022/081578
· Mar 18, 2022
· international
Continuity (3)
Continuation
PCTCN2022131861
· Nov 15, 2022
References Cited (216)
US 3854480A
· Zaffaroni
· 1974
[cited by applicant]
US 4452775A
· Kent
· 1984
[cited by applicant]
US 4675189A
· Kent et al.
· 1987
[cited by applicant]
US 5075109A
· Tice et al.
· 1991
[cited by applicant]
US 5133974A
· Paradissis et al.
· 1992
[cited by applicant]
US 5211657A
· Yamada et al.
· 1993
[cited by applicant]
US 5407686A
· Patel et al.
· 1995
[cited by applicant]
US 5736152A
· Dunn
· 1998
[cited by applicant]
US 7691997B2
· Khvorova et al.
· 2010
[cited by applicant]
US 8273866B2
· Mcswiggen et al.
· 2012
[cited by applicant]
US 8349809B2
· Brown
· 2013
[cited by applicant]
US 8513207B2
· Brown
· 2013
[cited by applicant]
US 8546350B2
· Bennett et al.
· 2013
[cited by applicant]
US 8618277B2
· Beigelman et al.
· 2013
[cited by applicant]
US 8927705B2
· Brown
· 2015
[cited by applicant]
US 9260471B2
· Cancilla et al.
· 2016
[cited by applicant]
US 9809819B2
· Brown
· 2017
[cited by applicant]
US 9970005B2
· Cancilla et al.
· 2018
[cited by applicant]
US 20050255487A1
· Khvorova et al.
· 2005
[cited by applicant]
US 20060217324A1
· Soutschek et al.
· 2006
[cited by applicant]
US 20080113351A1
· Naito
· 2008
[cited by applicant]
US 20110196141A1
· Vaijayanti et al.
· 2011
[cited by applicant]
US 20150297629A1
· Mullick et al.
· 2015
[cited by applicant]
US 20190345573A1
· Khvorova et al.
· 2019
[cited by applicant]
US 20240084304A1
· Shu et al.
· 2024
[cited by applicant]
US 20250257356A1
· Shu et al.
· 2025
[cited by applicant]
CN 101292034A
· 2008
[cited by applicant]
CN 102260673A
· 2011
[cited by applicant]
CN 103103192A
· 2013
[cited by applicant]
CN 106574268A
· 2017
[cited by applicant]
CN 108271351A
· 2018
[cited by applicant]
CN 112313335A
· 2021
[cited by applicant]
CN 113862268A
· 2021
[cited by applicant]
CN 114763547A
· 2022
[cited by applicant]
EP 3366772A1
· 2018
[cited by applicant]
EP 3812462A1
· 2021
[cited by applicant]
EP 4029520A1
· 2022
[cited by applicant]
EP 4403633A1
· 2024
[cited by applicant]
EP 4421175A1
· 2024
[cited by applicant]
WO WO199733623A1
· 1997
[cited by applicant]
WO WO2003070918A2
· 2003
[cited by applicant]
WO WO2003074654A2
· 2003
[cited by applicant]
WO WO2004045543A2
· 2004
[cited by applicant]
WO WO2007031081A2
· 2007
[cited by applicant]
WO WO2008137751A2
· 2008
[cited by applicant]
WO WO2010080129A2
· 2010
[cited by applicant]
WO WO2010111490A2
· 2010
[cited by applicant]
WO WO2011038356A2
· 2011
[cited by applicant]
WO WO2012058210A1
· 2012
[cited by applicant]
WO WO2012145582A2
· 2012
[cited by applicant]
WO WO2013074974A2
· 2013
[cited by applicant]
WO WO2013177468A2
· 2013
[cited by applicant]
WO WO2014130607A1
· 2014
[cited by applicant]
WO WO2014179625A1
· 2014
[cited by applicant]
WO WO2014179626A2
· 2014
[cited by applicant]
WO WO2014179627A2
· 2014
[cited by applicant]
WO WO2015168532A2
· 2015
[cited by applicant]
WO WO2015179724A1
· 2015
[cited by applicant]
WO WO2016028649A1
· 2016
[cited by applicant]
WO WO2016057693A1
· 2016
[cited by applicant]
WO WO2016100401A1
· 2016
[cited by applicant]
WO WO2016149331A2
· 2016
[cited by applicant]
WO WO2016196111A1
· 2016
[cited by applicant]
WO WO2017059223A2
· 2017
[cited by applicant]
WO WO2017062816A1
· 2017
[cited by applicant]
WO WO2017177326A1
· 2017
[cited by applicant]
WO WO2018035380A1
· 2018
[cited by applicant]
WO WO2018044350
· 2018
[cited by applicant]
WO WO2018044350A1
· 2018
[cited by examiner]
WO WO2018098328A1
· 2018
[cited by applicant]
WO WO2018185241A1
· 2018
[cited by applicant]
WO WO2019010342A1
· 2019
[cited by applicant]
WO WO2019051402A1
· 2019
[cited by applicant]
WO WO2019092283A1
· 2019
[cited by applicant]
WO WO2019145543A1
· 2019
[cited by applicant]
WO WO2019217397A2
· 2019
[cited by applicant]
WO WO2019222166A1
· 2019
[cited by applicant]
WO WO2020099476A1
· 2020
[cited by applicant]
WO WO2020123410A1
· 2020
[cited by applicant]
WO WO2020154342A1
· 2020
[cited by applicant]
WO WO2020191183A1
· 2020
[cited by applicant]
WO WO2020236526A1
· 2020
[cited by applicant]
WO WO2021049504A1
· 2021
[cited by applicant]
WO WO2021096763A1
· 2021
[cited by applicant]
WO WO2021119034A1
· 2021
[cited by applicant]
WO WO2021178885A1
· 2021
[cited by applicant]
WO WO2021234459A2
· 2021
[cited by applicant]
WO WO2022028457A1
· 2022
[cited by applicant]
WO WO2022032288A1
· 2022
[cited by applicant]
WO WO2022079221A1
· 2022
[cited by applicant]
WO WO2022159158A1
· 2022
[cited by applicant]
WO WO2022162155A1
· 2022
[cited by applicant]
WO WO2022232650A1
· 2022
[cited by applicant]
WO WO2023278576A1
· 2023
[cited by applicant]
WO WO2023014765A1
· 2023
[cited by applicant]
WO WO2023041079A1
· 2023
[cited by applicant]
WO WO2023041508A2
· 2023
[cited by applicant]
WO WO2023056446A1
· 2023
[cited by applicant]
WO WO2023066236A1
· 2023
[cited by applicant]
WO WO2023138689A1
· 2023
[cited by applicant]
WO WO2023192630A2
· 2023
[cited by applicant]
WO WO2024013334A1
· 2024
[cited by applicant]
WO WO2024031101A1
· 2024
[cited by applicant]
WO WO2024137700A2
· 2024
[cited by applicant]
WO WO2024187193A2
· 2024
[cited by applicant]
Duschmale et al., Nov. 22, 2019, vol. 48, No. 1, p. 63-74 (Year: 2019).
[cited by examiner]
Flamme et al., Jul. 1, 2021, Bioorganic & Medicinal Chemistry Letters, 48, 128242, p. 1-5 (Year: 2021).
[cited by examiner]
Ui-Tei et al., 2004, Nucleic Acids Research, vol. 32, No. 3, p. 936-948 (Year: 2004).
[cited by examiner]
Wooddell et al., Jun. 18, 2020, JCI Insight, 5(12):e135348 and Supplementary Materials (Year: 2020).
[cited by examiner]
ACTRN12622001430729p. “A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Adm…
[cited by applicant]
ACTRN12623000023651. “A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-0…
[cited by applicant]
Agrawal, Sudhir, et al. “Perspectives in antisense therapeutics.” Pharmacology & therapeutics 76.1-3 (1997): 151-160.
[cited by applicant]
Ausin, Cristina, et al. “Time-Dependent Thermocontrol of the Hydrophilic and Lipophilic Properties of DNA Oligonucleotide Prodrugs.” Current Protocols in Nucleic Acid Chemistry 43.1 (2010): 4-42.
[cited by applicant]
Bernstein, Emily, et al. “Role for a bidentate ribonuclease in the initiation step of RNA interference.” Nature 409.6818 (2001): 363-366.
[cited by applicant]
Campbell, Meghan A. et al. “Locked vs. unlocked nucleic acids (LNA vs. UNA): contrasting structures work towards common therapeutic goals.” Chemical Society Reviews 40.12 (2011): 5680-5689.
[cited by applicant]
Czauderna, Frank, et al. “Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells.” Nucleic acids research 31.11 (2003): 2705-2716.
[cited by applicant]
Du, Quan, et al. “A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sites.” Nucleic acids research 33.5 (2005): 1671-1677.
[cited by applicant]
Elbashir, Sayda M., et al. “RNA interference is mediated by 21- and 22-nucleotide RNAs.” Genes & development 15.2 (2001): 188-200.
[cited by applicant]
Elmen, Joacim, et al. “Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality.” Nucleic acids research 33.1 (2005): 439-447.
[cited by applicant]
Englisch, Uwe, et al. “Chemically modified oligonucleotides as probes and inhibitors.” Angewandte Chemie International Edition in English 30.6 (1991): 613-629.
[cited by applicant]
Gassmann, Max, et al. “Maintenance of an extrachromosomal plasmid vector in mouse embryonic stem cells.” Proceedings of the National Academy of Sciences 92.5 (1995): 1292-1296.
[cited by applicant]
Grunweller, Arnold, et al. “Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2′-O-methyl RNA, phosphorothioates and small interfering RNA.” Nucleic acids research 31.12 (2003):…
[cited by applicant]
International Search Report and Written Opinion from the International Searching Authority dated Jan. 19, 2023 from corresponding International Patent Application No. PCT/CN2022/131861 filed Nov. 15, 2022.
[cited by applicant]
Janas, Majam., et al. “Selection of GaINAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity.” Nature communications 9.1 (2018): 723.
[cited by applicant]
Kabanov, Alexander V., et al. “A new class of antivirals: antisense oligonucleotides combined with a hydrophobic substituent effectively inhibit influenza virus reproduction and synthesis of virus-specific proteins in M…
[cited by applicant]
Lam, Jenny KW, et al. “siRNA versus miRNA as therapeutics for gene silencing.” Molecular Therapy-Nucleic Acids 4 (2015): 1-20.
[cited by applicant]
Laursen, Maria B., et al. “Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo.” Molecular Biosystems 6.5 (2010): 862-870.
[cited by applicant]
Lee, Kyuri, et al. “The cutting-edge technologies of siRNA delivery and their application in clinical trials.” Archives of pharmacal research 41 (2018): 867-874.
[cited by applicant]
Letsinger, Robert L., et al. “Cholesteryl-conjugated oligonucleotides: synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture.” Proceedings of the National Acade…
[cited by applicant]
Manoharan, Muthiah, et al. “Chemical modifications to improve uptake and bioavailability of antisense oligonucleotides.” Annals of the New York Academy of Sciences 660.1 (1992): 306-309.
[cited by applicant]
Manoharan, Muthiah, et al. “Cholic acid-oligonucleotide conjugates for antisense applications.” Bioorganic & Medicinal Chemistry Letters 4.8 (1994): 1053-1060.
[cited by applicant]
Manoharan, Muthiah, et al. “Introduction of a lipophilic thioether tether in the minor groove of nucleic acids for antisense applications.” Bioorganic & Medicinal Chemistry Letters 3.12 (1993): 2765-2770.
[cited by applicant]
Manoharan, Muthiah, et al. “Lipidic nucleic acids.” Tetrahedron Letters 36.21 (1995): 3651-3654.
[cited by applicant]
Manoharan, Muthiah, et al. “Oligonucleotide conjugates: alteration of the pharmacokinetic properties of antisense agents.” Nucleosides, Nucleotides & Nucleic Acids 14.3-5 (1995): 969-973.
[cited by applicant]
Mishra, Rakesh Kumar, et al. “Improved leishmanicidal effect of phosphorotioate antisense oligonucleotides by LDL-mediated delivery.” Biochimica et Biophysica Acta (BBA)—Gene Structure and Expression 1264.2 (1995): 229-…
[cited by applicant]
Mook, Olaf R., et al. “Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo.” Molecular cancer therapeutics 6.3 (2007): 833-843.
[cited by applicant]
Nair, Jayaprakash K., et al. “Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing.” Journal of the American Chemical Society 136.49 (2014): 16958-1…
[cited by applicant]
Nikam, Rah UL R., et al. “Journey of siRNA: clinical developments and targeted delivery.” Nucleic acid therapeutics 28.4 (2018): 209-224.
[cited by applicant]
Nykanen, Antti, et al. “ATP requirements and small interfering RNA structure in the RNA interference pathway.” Cell 107.3 (2001 ): 309-321.
[cited by applicant]
Oberhauser, Berndt et al. “Effective incorporation of 2′-O-methyl-oligoribonuclectides into liposomes and enhanced cell association through modification with thiocholesterol.” Nucleic Acids Research 20.3 (1992): 533-538.
[cited by applicant]
Olearczyk, Jeffrey, et al. “Targeting of hepatic angiotensinogen using chemically modified siRNAs results in significant and sustained blood pressure lowering in a rat model of hypertension.” Hypertension Research 37.5 …
[cited by applicant]
Reboussin, David M., et al. “Systematic review for the 2017 ACC/AHA/MPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report …
[cited by applicant]
Saison-Behmoaras, T., et al. “Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation.” The EMBO journal 10.5 (1991 ): 1…
[cited by applicant]
Sawhney, Amarpreet S., et al. “Bioerodible hydrogels based on photopolymerized poly (ethylene glycol)-co-poly (alpha-hydroxy acid) diacrylate macromers.” Macromolecules 26.4 (1993): 581-587.
[cited by applicant]
Shea, Regang., et al. “Synthesis, hybridization properties and antiviral activity of lipid-oligodeoxynucleotide conjugates.” Nucleic acids research 18.13 (1990): 3777-3783.
[cited by applicant]
Springer, Aaron D., et al. “GaINAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics.” Nucleic acid therapeutics 28.3 (2018): 109-118.
[cited by applicant]
Svinarchuk, F. P., et al. “Inhibition of HIV proliferation in MT-4 cells by antisense oligonucleotide conjugated to lipophilic groups.” Biochimie 75.1-2 (1993): 49-54.
[cited by applicant]
Uijl, Estrellita, et al. “Strong and sustained antihypertensive effect of small interfering RNA targeting liver angiotensinogen.” Hypertension 73.6 (2019): 1249-1257.
[cited by applicant]
Vaish, Narendra et al. “Improved specificity of gene silencing by siRNAs containing unlocked nucleobase analogs.” Nucleic acids research 39.5 (2011): 1823-1832.
[cited by applicant]
Whelton, Paulk., et al. “2017 ACC/AHA/MPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Car…
[cited by applicant]
ACTRN12623001200673. “A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-2…
[cited by applicant]
Allerson et al. (2005) “Fully 2′-Modified Oligonucleotide Duplexes with Improved in Vitro Potency and Stability Compared to Unmodified Small Interfering RNA” J Med Chem, (48):901-904.
[cited by applicant]
Anderson et al., (2021) “Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides” Nucleic Acids Resear…
[cited by applicant]
Beaucage et al., (1992) “Advances in the Synthesis of Oligonucleotides by the Phosphoramidite Approach” Tetrhedron, 48(12): 2223-2311.
[cited by applicant]
Biscans et al., (2019) “Diverse lipid conjugates for functional extra-hepatic siRNA delivery in vivo” Nucleic Acids Research, 47(3):1082-1096.
[cited by applicant]
Cook., (1998) “Chapter 2: Antisense Medicinal Chemistry” Antisense Research and Application,131:51-101.
[cited by applicant]
Crooke et al., (1996) “Pharmacokinetic Properties of Several Novel Oligonucleotide Analogs in Mice” The Journal of Pharmacology and Experimental Therapeutics, 277(2):923-937.
[cited by applicant]
Ding et al., (2014) “Direct Cytosolic siRNAdelivery by Reconsitituted High Density Lipoprotein for Target-Specific Therapy of Tumor Angiogenesis” Biomaterials, 35:7214-7227.
[cited by applicant]
Duschmale et al., (2019) “In vitro and in vivo properties of therapeutic oligonucleotides containing non-chiral 3′ and 5′ thiophosphate linkages” Nucleic Acids Research, 48:63-74.
[cited by applicant]
Elbashir et al., (2001) “RNA interference is mediated by 21- and 22-nucleotide RNAs” Genes & Development, 15:188-200.
[cited by applicant]
Flamme et al., (2021) “Towards the enzymatic synthesis of phosphorothioate containing LNA oligonucleotides” Bioorganic & Medicinal Chemistry Letters, 48(128242):1-5.
[cited by applicant]
Gonzalez-Carmona et al., (2013) “Inhibition of hepatitis C virus RNA translation by antisense bile acid conjugated phosphorothioate modified oligodeoxynucleotides (ODN)” Antiviral Research, 97(1):49-59.
[cited by applicant]
International Search Report and Written Opinion from the International Searching Authority dated May 8, 2023 from corresponding International Patent Application No. PCT/CN2023/073456 filed on Jan. 23, 2023.
[cited by applicant]
Herdewijn et al., (2008) “Modified Nucleosides: in Biochemistry, Biotechnology and Medicine”.
[cited by applicant]
Huang., (2019) “Approval of the first-ever rnai therapeutics and its technological development history” Progress in Biochemistry and Biophysics, 46(3):313-322.
[cited by applicant]
Jayaprakash et al., (2014) “Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing” J. Am. Chem. Soc., 136:16958-16961.
[cited by applicant]
Juliano et al., (2011) “Integrin Targeted Delivery of Gene Therapeutics” Theranostics, 1:211-219.
[cited by applicant]
Knerr et al., (2021) “Glucagon Like Peptide 1 Receptor Agonists for Targeted Delivery ofAntisense Oligonucleotides to Pancreatic Beta Cell” J. Am. Chem. Soc., 143:3416-3429.
[cited by applicant]
Liu et al., (2018) “An Investigational RNAi Therapeutic Targeting Factor XII (ALN-F12) for the Treatment of Hereditary Angioedema” RNA, 25:255-263.
[cited by applicant]
Lonnberg et al., (2017) “Synthesis of oligonucleotides on a soluble support” Beilstein J. Org. Chem, 13:1368-1387.
[cited by applicant]
Martin et al., (1995) “A New Access to 2′-O-Alkylated Ribonucleosides and Properties of 2′-O-Alkylated Oligoribonucleotides” Helvetica Chimica Acta, 78(2):486-504.
[cited by applicant]
Office Action in U.S. Appl. No. 19/084,507, mailed May 23, 2025, 26 pages.
[cited by applicant]
Osborn et al., (2018) “Improving Small Interfering RNA Delivery In Vivo Through Lipid Conjugation” Nucleic and Therapeutics, 28(3):1-9.
[cited by applicant]
Pon., (2000) “Solid-phase supports for oligonucleotide synthesis” Current Protocols in Nucleic Acid Chemistry, 3.1.1-3.1.28.
[cited by applicant]
Prakash et al., (2019) “Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle” Nucleic Acids Research, 47(12):6029-6044.
[cited by applicant]
Qian et al., (2002) “Targeted Drug Delivery via the Transferrin Receptor—Mediated Endocytosis Pathway” Pharmacological Reviews,54(4):561-587.
[cited by applicant]
Raouane et al., (2012) “Lipid Conjugated Oligonucleotides: A Useful Strategy for Delivery” Bioconjugate Chemistry, 23:1091-1104.
[cited by applicant]
Rashad et al., (2019) “Chapter 8: Click Chemistry for Cyclic Peptide Drug Design” Cyclic Peptide Design, Methods in Molecular Biology, 133-145.
[cited by applicant]
Sharma et al., (2018) “Novel Cluster and Monomer-Based GaINAc Structures Induce Effective Uptake of siRNAs in Vitro and in Vivo” Bioconjugate Chemistry,29:2478-2488.
[cited by applicant]
Sharp et al., (2001) “RNA interference—2001” Genes Development, 15:485-490.
[cited by applicant]
Tetko et al., (2001) “Prediction of n-Octanol/Water Partition Coefficients from PHYSPROP Database Using Artificial Neural Networks and E-State Indices” J. Chem. Inf. Comput. Sci, 41:1407-1421.
[cited by applicant]
Ui-Tei et al., (2004) “Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference” Nucleic Acids Research, 32:936-948.
[cited by applicant]
Wooddell et al., (2020) “Development of an RNAi therapeutic for alpha-1-antitrypsin liver disease” JCI Insight, 5(el35348):1-56.
[cited by applicant]
Zhao et al., (2008) “Targeted drug delivery via folate receptors” Expert Opin. Drug Deliv.,5(3):309-319.
[cited by applicant]
U.S. Appl. No. 18/730,467, filed Jan. 23, 2023, by Shu et al.
[cited by applicant]